Arc 4The Alzheimer’s Breakthrough
Wei Kang and Chen Yiqing developed Sanqing’s Alzheimer’s drug and proved its promise through clinical trials. After a smear campaign and international pressure, Sanqing pursued overseas markets independently and released the drug, leaving patients and families facing its price.
- Wei Kang offered Chen Yiqing the R&D director position, and Chen accepted to lead Sanqing’s Alzheimer’s research.
- Wei Kang used the system to create a γ-secretase inhibitor, and Chen Yiqing, Wenren Long, and Tang Que synthesized and optimized it.
- Old Man Xie improved during the drug trial, and Sanqing’s researchers published promising results that drew worldwide attention.
- Pfizer executives encouraged Fox News to accuse Chen Yiqing of stealing research, but the allegations triggered backlash and Sanqing suspended overseas applications.
- Three Purities released patient data and a recovery documentary, while Fox News apologized after its coverage failed to discredit the drug.
- Wei Kang prioritized domestic trials, then Sanqing exchanged access to the drug for technology and equipment and chose to manage overseas sales itself.
- Sanqing’s trials drew patients worldwide, and Amy recovered after learning she had hereditary Alzheimer’s disease.
- Sanqing announced its Phase III results and release date, then officially launched its Alzheimer’s drug after families anxiously debated its affordability.